Skip to main content
Clinical Trials/NCT04240990
NCT04240990CompletedNot Applicable

Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition

Institut National de la Santé Et de la Recherche Médicale, France3 sites in 2 countries603 target enrollmentStarted: November 4, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
603
Locations
3
Primary Endpoint
Specificity of the score obtained

Study Overview

Brief Summary

TB-Speed SAM is a multicentric, prospective diagnostic cohort study conducted in two countries with high and very high TB incidence (Uganda and Zambia). It aims at assessing several diagnostic tests that could result in the development of a score and algorithm for TB treatment decision in hospitalised children with severe acute malnutrition (SAM).

Detailed Description

There is now strong evidence that undiagnosed and untreated TB increases the risk of death in children, especially those severely malnourished who are highly vulnerable. Specific decision-making tools are therefore urgently needed to guide clinicians from high TB burden and low-income countries to initiate treatment quickly in children with SAM with suspected TB.

A diagnostic prediction score and algorithm was recently proposed by the investigators for TB treatment decision in HIV-infected children with presumptive TB (developed in the ANRS 12229 PAANTHER 01 study). Based on easily collected clinical features, chest X-Ray (CXR), Xpert MTB/RIF, and abdominal ultrasonography, the score aims to help clinicians make a same-day treatment decision. Such a prediction score improving TB diagnosis and shortening time to treatment initiation would be a key benefit in children with SAM.

Based on this experience, the investigators are proposing a diagnostic cohort study enrolling hospitalized severely malnourished children. The study will include the evaluation of several diagnostic tests that could be integrated in the development of a prediction model and subsequent score for the diagnosis of TB in hospitalized children with SAM. This will include Xpert MTB/RIF Ultra performed on one nasopharyngeal aspirate (NPA) and one stool sample, CXR, Quantiferon (QFT) Interferon-Gamma Release Assay (IGRA), Monocyte-to-lymphocyte ratio (MLR), and ultrasonography, which has shown its interest for the diagnosis of TB in both HIV-infected adults and children. In the PAANTHER study, it detected abdominal lymphadenopathy in 50% of culture confirmed TB cases and 35% of all confirmed and unconfirmed cases, with a specificity of 85%.

Using logistic regression, a score will be developed for TB diagnosis, considering confirmed and unconfirmed TB as reference diagnosis, in hospitalized children with SAM. As a secondary objective, and in order to reduce costs, sample collection, and complexity of the diagnostic process, a first-step screening score (excluding Ultra, abdominal ultrasound, and CXR if possible) will be developed to identify children with presumptive TB who would benefit from further diagnostic testing.

Both scores will be internally validated using resampling and will be incorporated in a stepwise algorithm to guide practical implementation of the screening and diagnosis process. The stepwise algorithm will be discussed with local clinicians involved in the study to better adapt it for future use in their routine practice.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
2 Months to 59 Months (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Children aged 2 to 59 months
  • •Severe acute malnutrition defined as weight-for-height Z score (WHZ) < -3 standard deviation (SD) or mid-upper arm circumference (MUAC) < 115 mm (in children over 6 months) or clinical signs of bilateral pitting oedema
  • •Hospitalized per hospital clinician's decision
  • •Parent/guardian informed consent

Exclusion Criteria

  • •- Ongoing TB treatment or history of intake of anti-TB drugs in the last 3 months

Arms & Interventions

Prospective cohort

Experimental

Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.

Intervention: Development of a score and algorithm for TB treatment decision in hospitalised children with SAM. (Other)

Outcomes

Primary Outcomes

Specificity of the score obtained

Time Frame: 6 months

Specificity of the score obtained using predicted probability cut-off with the prediction model for the diagnosis of TB

Sensitivity of the score obtained

Time Frame: 6 months

Sensitivity of the score obtained using predicted probability cut-off with the prediction model for the diagnosis of TB, defined as either confirmed or unconfirmed using the updated Clinical Case Definition for Classification of Intrathoracic Tuberculosis

Secondary Outcomes

  • Mortality at 6 months(6 months)
  • Percentage weight gain 6 months(6 months)
  • Prevalence of TB among hospitalized children with SAM(6 months)
  • Clinical characteristics of TB disease in hospitalized children with SAM(6 months)
  • Bacteriological characteristics of TB disease in hospitalized children with SAM(6 months)
  • Biological characteristics of TB disease in hospitalized children with SAM(6 months)
  • Radiological characteristics of TB disease in hospitalized children with SAM(6 months)
  • Sensitivity of the score obtained(6 months)
  • Specificity of the score obtained(6 months)
  • Estimated time to TB treatment decision in hospitalized children with SAM(6 months)
  • Diagnostic accuracy measures: 1/ Sensitivity of the different tests evaluated for the diagnosis of TB(6 months)
  • Diagnostic accuracy measures: 2/ Specificity of the different tests evaluated for the diagnosis of TB(6 months)
  • Diagnostic accuracy measures: 3/ Negative predictive value of the different tests evaluated for the diagnosis of TB(6 months)
  • Diagnostic accuracy measures: 4/ Positive predictive value of the different tests evaluated for the diagnosis of TB(6 months)
  • Diagnostic accuracy measures: 5/ AUROC of diagnostic prediction models with and without the different tests results(6 months)
  • Diagnostic accuracy of Ultra performed on one NPA and one stool sample against a specific microbiological reference standard including Ultra and mycobacterial culture from gastric aspirates(6 months)
  • Proportion of children with NPA and stool samples collected as per study protocol(6 months)
  • Proportion of NPA-related adverse events (AEs)(6 months)
  • Tolerability of NPA collection: 1/ Discomfort/pain/distress experienced by the child as assessed by the child(Within 3 days of inclusion)
  • Tolerability of NPA collection: 2/ Discomfort/pain/distress experienced by the child as assessed by the parents(Within 3 days of inclusion)
  • Tolerability of NPA collection: 3/ Discomfort/pain/distress experienced by the child as assessed by the nurse(Within 3 days of inclusion)
  • TB treatment outcomes(6 months)

Investigators

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Sponsor Class
Other Gov
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials